WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Rita Ora, 33, and husband Taika Waititi, 48, put on a very lovedKing Charles bursts into laughter as highPakistan records its wettest April since 1961 with above average rainfallA look back at all the times Margot Robbie has served as a bridesmaidPaige VanZant claims Dillon Danis asked her to 'peg him' as her husband challenges him to fightBen Yedder scores two as Monaco beats Clermont 4Troyes fans and players throw flares at each other after 2ndUnited Methodist delegates repeal their church’s ban on its clergy celebrating sameClosing prices for crude oil, gold and other commoditiesGypsy Rose Blanchard, 32, shows off new nose after undergoing plastic surgery
3.4467s , 6516.8515625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,World Wave news portal